🟢 BioCryst Pharmaceuticals is trading 6.8% up today after beating Q2 estimates and raising its FY26 revenue outlook

BioCryst Pharmaceuticals is trading 6.8% up at $9.63 after reporting better-than-expected second-quarter 2026 results and raising its full-year revenue guidance.

• The company posted Q2 revenue of $218.3 million and EPS of $0.30, beating consensus estimates, bolstered by $55.7 million recognized from a European licensing deal for navenibart.
• Management raised its total 2026 revenue guidance to a range of $690–$715 million while maintaining core ORLADEYO guidance unchanged.